Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Clobetasol propionate
Drug ID BADD_D00490
Description Clobetasol propionate is a prednisolone derivative with higher specificity for glucocorticoid receptors than mineralocorticoid receptors.[L11815] It has demonstrated superior activity compared to [fluocinonide][A190963] and was first described in the literature in 1974.[A190936] Clobetasol Propionate was granted FDA approval on 27 December 1985.[L11809]
Indications and Usage Clobetasol propionate is indicated to treat moderate to severe plaque psoriasis[L11818,L118121,L11824] as well as inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.[L11815,L11827]
Marketing Status approved
ATC Code D07AD01
DrugBank ID DB01013
KEGG ID D01272
MeSH ID D002990
PubChem ID 32798
TTD Drug ID D0H0YD
NDC Product Code 79572-008; 42291-077; 50383-267; 51672-4193; 60429-902; 68071-2725; 0472-0403; 70771-1442; 52128-158; 16714-030; 0168-0163; 45802-437; 49502-537; 50383-269; 51672-1259; 62332-486; 63629-2393; 68382-998; 68462-529; 46439-8747; 33342-321; 43386-096; 50742-304; 51672-1258; 0299-3847; 62559-980; 63629-2395; 68462-532; 70700-106; 70710-1401; 71589-002; 0299-3849; 62332-707; 63646-500; 68180-956; 70710-1456; 71589-018; 22552-0006; 13668-569; 43538-952; 43538-953; 45802-925; 50090-5778; 50090-6402; 50383-978; 50383-979; 63629-2329; 63629-2392; 0378-8055; 68071-2764; 68788-8238; 70700-109; 71205-151; 72578-085; 51552-0605; 42571-362; 43538-950; 0168-0269; 50383-268; 51672-1293; 63629-2331; 63629-8637; 69238-1532; 71428-005; 0713-0656; 46439-8708; 49452-2141; 62991-1492; 42291-076; 63629-2332; 0591-4039; 43386-028; 0168-0162; 0168-0301; 50090-5079; 62332-465; 63629-2394; 63629-9461; 0378-8147; 68462-608; 70771-1209; 71085-007; 72189-262; 51927-2627; 40032-028; 0168-0293; 45802-637; 50090-5488; 51672-1350; 62332-548; 63629-2330; 63629-8639; 64980-441; 66993-939; 68180-536; 68462-530; 0472-0404; 70752-153; 70771-1080; 40032-096; 51672-1294; 51672-1371; 0299-3848; 62332-425; 62332-547; 63629-8638; 63629-9460; 68180-551; 68462-480; 68462-625; 69238-1732; 70771-1498; 64958-0101; 76003-0325; 16714-782; 45802-961; 50090-5264; 50383-266; 51672-1297; 51672-1347; 53002-9970
UNII 779619577M
Synonyms Clobetasol | Clofenazon | Clobetasol Propionate | Clobetasol 17-Propionate | Clobetasol 17 Propionate | Clobex | Cormax | OLUX | Dermovate | Embeline | Embeline E | Temovate
Chemical Information
Molecular Formula C25H32ClFO5
CAS Registry Number 25122-46-7
SMILES CCC(=O)OC1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)C(=O)CCl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin hypopigmentation23.05.02.003--
Skin irritation23.03.04.0090.006349%Not Available
Skin striae23.01.05.0020.015498%Not Available
Skin ulcer23.07.03.003; 24.04.03.0070.012697%
Small intestinal obstruction07.13.06.001--
Syncope24.06.02.012; 17.02.04.008; 02.11.04.0150.001867%
Telangiectasia24.03.03.003; 23.06.03.001--
Tenderness08.01.08.005--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Withdrawal syndrome08.06.02.012; 19.07.06.0230.001867%Not Available
Skin maceration23.03.03.016--Not Available
Dermatosis23.03.03.0170.004108%Not Available
Application site dryness08.02.01.011; 23.03.03.024; 12.07.01.011--Not Available
Emotional distress19.04.02.008--Not Available
Eye pruritus06.04.05.006--Not Available
Musculoskeletal discomfort15.03.04.0010.004108%Not Available
Skin burning sensation17.02.06.009; 23.03.03.0210.025395%Not Available
Dyslipidaemia14.08.04.0150.001867%Not Available
Asteatosis23.02.07.006--Not Available
Application site discolouration23.03.03.023; 12.07.01.030; 08.02.01.030--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Pituitary tumour benign05.03.05.003; 16.37.02.0010.001867%Not Available
Immunosuppression10.03.02.001--Not Available
Lipohypertrophy23.07.01.005; 14.08.04.0090.001867%
Unevaluable event08.01.03.0510.004108%Not Available
Erosive oesophagitis07.04.05.0040.001867%Not Available
Application site burn23.03.11.013; 12.07.01.038; 08.02.01.038--Not Available
Central obesity14.03.02.0110.002801%Not Available
Type 1 diabetes mellitus14.06.01.010; 10.04.08.007; 05.06.01.0100.002801%Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages